Daniel R. Chard

Daniel R. Chard (chief executive) discloses dealings in Medifast Inc to SEC (Form 4). We count 20 filings; the first trade dates from 11 June 2021 and the latest from 29 September 2026.

On the open market, the record shows 3 purchases worth €192k and 5 sales worth €833k. Sales outweigh purchases by €642k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 10 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 2 sales.

Half of the purchases are above €75k and half below. 2 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 33% of cases, with a median move of -24.7%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 30 September 2026 with an open-market sale (€100k) in Medifast Inc. The latest purchase dates back some time: it was published 488 days ago, on 17 June 2025. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.